The ability of human cochlear hair cells to regenerate has been nothing more than a pipe dream – until recently. Frequency Therapeutics, a publicly traded (NASDAQ) company based in Lexington, Massachusetts, has published a series of clinical trials showing early promise that a pharmacologic agent, FX-322, regenerates human hair cells in the cochlea.   

During this interview with Brian Taylor, Frequency's Kevin Franck, PhD, SVP of Strategic Marketing and New Product Planning, and Carl LeBel, PhD, Chief Development Officer, review biology of progenitor cells, their published clinical trials data and current status of a larger, blinded placebo control trial.